Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Oncodesign and Banook Central Imaging Sign a Collaboration Agreement

Published: Tuesday, September 10, 2013
Last Updated: Monday, September 09, 2013
Bookmark and Share
The global reaching partnership aims to provide clinical researchers with new biomarkers and validated image analysis protocols, ensuring a continuum from preclinical to clinical phase in the development of anticancer therapies.

Oncodesign and Banook Central Imaging have announced the start of a partnership to expand the use of new approaches in pharmaco-imaging.

The partners expect to share expertise, co-promote joint activities and jointly engage in scientific collaboration to standardize image acquisition and analysis protocols in early clinical phases.

The financial details of the agreement were not disclosed.

The various medical imaging procedures (computed tomography, magnetic resonance imaging, positron emission tomography, single-photon emission computed tomography and ultrasound imaging) have become indispensable tools in early-stage development of anticancer compounds.

The information they provide about the disease and the effects of molecules is highly valuable in identifying translational markers in preclinical and clinical phases.

The partnership between Oncodesign and Banook Central Imaging breaks new ground in the evaluation of anticancer therapies by helping to guide a compound from research laboratory to patient through the pursuit of greater consistency in the imaging protocols used during the development cycle, in accordance with good clinical practice.

The first phase of this partnership will last three years. First results are expected by early 2014.

“Oncodesign leads the way in pharmaco-imaging. As well as conducting preclinical proofs of concept, we have a long tradition of striving to provide our clients with tools for improving the characterization of their molecule's therapeutic potential, to expedite clinical trials in humans,” said Philippe Genne, PhD, CEO and founder of Oncodesign.

Genne continued, “In the coming weeks, our partnership with Banook Central Imaging will help us to provide our clients with practical solutions, ensuring that the measure of efficacy of anticancer therapies is attainable from one phase of development to the next.”

“It is crucial that the challenges of standardizing biomarkers in pharmaco-imaging are considered from the early phases of clinical development,” said Dr Pascal Voiriot, MSc, chairman of Banook Central Imaging.

Dr Voiriot continued, “Our partnership with Oncodesign is in line with our strategy which aims to implement relevant biomarkers in medical imaging, focusing ultimately on personalized medicine and the ability to produce a considerable time saving for the direct benefit of research laboratories and patients.”

A joint announcement about the partnership will be made at the ESMO (European Society for Medical Oncology) conference to be held in Amsterdam, the Netherlands, from September 27 to October 1.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oncodesign Enters into a Services Agreement with Eisai
The program aims to identify useful patient stratification biomarkers for Eisai’s Halaven® eribulin using patient-derived xenograft models.
Friday, December 26, 2014
Oncodesign and UCB Enter into a Research Collaboration
The partnership is based on Oncodesign's Nanocyclix® technology platform for next generation kinase inhibitors and UCB’s expertise in neurology.
Thursday, November 14, 2013
Oncodesign Signs a Partnership Agreement with Sanofi
Oncodesign will apply its Nanocyclix® technology to one of Sanofi's kinase targets.
Tuesday, April 09, 2013
Oncodesign Signs Partnership Agreement with Sanofi
Oncodesign will apply its Nanocyclix(R) technology to one of Sanofi's kinase targets.
Thursday, March 28, 2013
Oncodesign and OSEO Announce Funding of EUR 13.4 Million
This private-public partnership project, which aims to put in place the first national subsidiary dedicated to personalized medicine in oncology, has a EUR 41 million overall investment budget.
Tuesday, March 12, 2013
Oncodesign and the LNGT Enter into a Research Collaboration
Collaboration to advance Oncodesign's Parkinson’s disease program towards clinical development.
Wednesday, December 19, 2012
Oncodesign Enters into a Research Collaboration and License Agreement with Sanofi
Collaboration for the application of Oncodesign’s Nanocyclix® technology to Sanofi’s kinase targets.
Saturday, September 15, 2012
Oncodesign and Ipsen Enter into a Research Collaboration
Partnership is based on Oncodesign's Nanocyclix(R) Technology for next generation kinase inhibitors and Ipsen’s expertise in Movement Disorders.
Thursday, January 05, 2012
Oncodesign and Ipsen Enter Into a Research Collaboration
Partnership is based on Oncodesign's Nanocyclix® technology for next generation kinase inhibitors and Ipsen’s expertise in movement disorders.
Thursday, January 05, 2012
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Manufactured Stem Cells to Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Dengue Virus Exposure May Amplify Zika Infection
Researchers at Imperial College London have found that the previous exposure to the dengue virus may increase the potency of Zika infection.
Gender Determination in Forensic Investigations
This study investigated the effectiveness of lip print analysis as a tool in gender determination.
Identifying Novel Types of Forensic Markers in Degraded DNA
Scientists have tried to verify the nucleosome protection hypothesis by discovering STRs within nucleosome core regions, using whole genome sequencing.
Proteins in Blood of Heart Disease Patients May Predict Adverse Events
Nine-protein test shown superior to conventional assessments of risk.
Higher Frequency of Huntington's Disease Mutations Discovered
University of Aberdeen study shows that the gene change that causes Huntington's disease is much more common than previously thought.
Starving Stem Cells May Enable Scientists To Build Better Blood Vessels
Researchers from the University of Illinois at Chicago College of Medicine have uncovered how changes in metabolism of human embryonic stem cells help coax them to mature into specific cell types — and may improve their function in engineered organs or tissues.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!